NUWE Overview

Nuwellis, Inc. is a commercial-stage medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.

Wall Street analysts forecast NUWE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUWE is5.50 USD with a low forecast of 5.50 USD and a high forecast of 5.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Nuwellis Inc revenue for the last quarter amounts to 2.22M USD, decreased -6.34

Nuwellis Inc. EPS for the last quarter amounts to 0.56 USD, decreased -99.24

Nuwellis Inc (NUWE) has 38 emplpoyees as of March 11 2026.

Today NUWE has the market capitalization of 2.44M USD.